Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4956648 | 1.00 | CYP3A4 (0.32) | CYP3A4MIFGABRA1GABRB2CYP1A2 | |
| SCHEMBL12865532 | 0.84 | APOBEC3G (0.31) | — | |
| SCHEMBL1009278 | 0.84 | MIF (0.44) | CYP3A4MIF | |
| SCHEMBL707583 | 0.80 | CYP3A4 (0.34) | CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL28048338 | 0.77 | LIPG (0.46) | CYP3A4CYP2D6 | |
| SCHEMBL28536551 | 0.77 | GABRA1 (0.50) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL28658322 | 0.77 | GABRA1 (0.42) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL11167797 | 0.74 | APLNR (0.34) | — | |
| Pyridine SCHEMBL7848227 | 0.74 | MIF (0.36) | MIF | |
| SCHEMBL18245040 | 0.73 | NOS3 (0.36) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852478-A | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | 格莱克罗吉克斯公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-115697352-B | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | 格莱克罗吉克斯公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-115697352-A | Sulfated glycosaminoglycan biomaterials as proteoglycan mimetics | 格莱克罗吉克斯公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4121064-A1 | SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS | Glycologix, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11541075-B2 | Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid | ANIKA THERAPEUTICS, INC. | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541075-B2 | Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid | CD44, APEH, IDE | CYP3A4 2474/4885MIF 324/4885GABRA1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.